Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
EOLIA
About the Trial
The ECMO to Rescue Lung Injury in Severe ARDS trial randomized 249 patients with very severe ARDS to early VV ECMO or conventional management with transfer allowance. Mortality at 60 days, the primary endpoint, was 35 versus 46 percent, not statistically significant, and emergency crossover of 28 percent of control patients to ECMO complicated interpretation. The trial was stopped early for futility. The 2018 publication, followed by a Bayesian reanalysis by Goligher and colleagues suggesting a probable mortality benefit, ignited debate about crossovers, stopping rules, and statistical interpretation. With the earlier CESAR trial, EOLIA supported ECMO as a rescue option for refractory ARDS at experienced centers, and it was used widely during COVID 19 surges.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...